Literature DB >> 26156837

Moxonidine for tramadol withdrawal symptoms during detoxification.

Farid Talih1, Elias Ghossoub1.   

Abstract

It is well documented in the literature that noradrenergic pathways are key in the manifestation of opioid withdrawal symptoms, which is why clonidine is used as an off-label agent in opioid detoxification regimens given its anti-sympathetic properties. Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no α2-adrenergic agonist activity and subsequently fewer side effects. We report the case of a 33-year-old woman with a 15-year history of tramadol use who was admitted voluntarily for detoxification. She was started on moxonidine and had an uneventful detoxification. Two months after discharge, the patient maintained tramadol abstinence with good tolerability to moxonidine. To the best of our knowledge, this has not been previously reported in the medical literature. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26156837      PMCID: PMC4499750          DOI: 10.1136/bcr-2015-210444

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Alpha2-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael F Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2014-03-31

Review 2.  Pharmacological properties of the central antihypertensive agent, moxonidine.

Authors:  Lincoln P Edwards; Terry A Brown-Bryan; Lancelot McLean; Paul Ernsberger
Journal:  Cardiovasc Ther       Date:  2011-04-05       Impact factor: 3.023

Review 3.  Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence.

Authors:  R Maldonado
Journal:  Neurosci Biobehav Rev       Date:  1997-01       Impact factor: 8.989

4.  Alpha(2) receptors and agonists in pain management.

Authors:  H Smith; J Elliott
Journal:  Curr Opin Anaesthesiol       Date:  2001-10       Impact factor: 2.706

Review 5.  The imidazoline receptor in control of blood pressure by clonidine and allied drugs.

Authors:  D J Reis; J E Piletz
Journal:  Am J Physiol       Date:  1997-11

6.  Role of imidazoline receptors in the anti-aversive properties of clonidine during opiate withdrawal in rats.

Authors:  F Georges; S Caillé; C Vouillac; C Le Moine; L Stinus
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

Review 7.  Imidazoline receptors and human brain disorders.

Authors:  J A García-Sevilla; P V Escribá; J Guimón
Journal:  Ann N Y Acad Sci       Date:  1999-06-21       Impact factor: 5.691

8.  Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla.

Authors:  P Ernsberger; R Giuliano; R N Willette; A R Granata; D J Reis
Journal:  J Hypertens Suppl       Date:  1988-12

Review 9.  Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.

Authors:  Emily C Gish; Jamie L Miller; Brooke L Honey; Peter N Johnson
Journal:  Ann Pharmacother       Date:  2009-12-29       Impact factor: 3.154

Review 10.  Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia.

Authors:  Laura S Stone; Carolyn A Fairbanks; George L Wilcox
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.